3IAR - JenaLib

Asym./Biol. Unit (Jmol Viewer)

Asym./Biol. Unit - sites (Jmol Viewer)

Title :   THE CRYSTAL STRUCTURE OF HUMAN ADENOSINE DEAMINASE

Authors :   E. Ugochukwu, Y. Zhang, E. Hapka, W. W. Yue, J. E. Bray, J. Muniz, N. Burge A. Chaikuad, F. Von Delft, C. Bountra, C. H. Arrowsmith, J. Weigelt, A K. L. Kavanagh, U. Oppermann, Structural Genomics Consortium (Sg

Date :   14 Jul 09 (Deposition) - 11 Aug 09 (Release) - 13 Jul 11 (Revision)

Method :   X-RAY DIFFRACTION

Resolution :   1.52

Chains :   Asym./Biol. Unit : A

Keywords :   Deaminase, Adenosine Deaminase, Adenosine, Purine Metabolism, Structural Genomics, Structural Genomics Consortium, Sgc, Disease Mutation, Hereditary Hemolytic Anemia, Hydrolase, Nucleotide Metabolism, Scid (Keyword Search: [Gene Ontology, PubMed, Web (Google)] )

Reference :   E. Ugochukwu, Y. Zhang, E. Hapka, W. W. Yue, J. E. Bray, J. Muniz, N. Burgess-Brown, A. Chaikuad, K. L. Kavanagh, U. Oppermann
The Crystal Structure Of Human Adenosine Deaminase
To Be Published
PubMed: search

Molecule 1 - ADENOSINE DEAMINASE
	Chains	:	A
	EC Number	:	3.5.4.4
	Engineered	:	YES
	Expression System	:	ESCHERICHIA COLI
	Expression System Plasmid	:	PNIC-CTHF
	Expression System Strain	:	BL21(DE3)-R3-PRARE2
	Expression System Taxid	:	562
	Fragment	:	UNP RESIDUES 5-363
	Gene	:	ADA
	Organism Common	:	HUMAN
	Organism Scientific	:	HOMO SAPIENS
	Organism Taxid	:	9606
	Synonym	:	ADENOSINE AMINOHYDROLASE

		1
Asymmetric/Biological Unit	:	A

Summary Information (see also Sequences/Alignments below)

Asymmetric/Biological Unit (4, 5)

No.	Name	Count	Type	Full Name
1	3D1	1	Ligand/Ion	(2R,3S,5R)-5-(6-AMINO-9H-PURIN-9-YL)-TETRAHYDRO-2-(HYDROXYMETHYL)FURAN-3-OL
2	GOL	1	Ligand/Ion	GLYCEROL
3	NI	1	Ligand/Ion	NICKEL (II) ION
4	NO3	2	Ligand/Ion	NITRATE ION

Asymmetric Unit (5, 5)

No.	Name	Evidence	Residues	Description
1	AC1	SOFTWARE	NI A:1 , HIS A:17 , ASP A:19 , LEU A:62 , PHE A:65 , LEU A:106 , GLY A:184 , HIS A:214 , GLU A:217 , HIS A:238 , ASP A:295 , ASP A:296 , HOH A:781 , HOH A:814	BINDING SITE FOR RESIDUE 3D1 A 501
2	AC2	SOFTWARE	HIS A:15 , HIS A:17 , HIS A:214 , ASP A:295 , 3D1 A:501	BINDING SITE FOR RESIDUE NI A 1
3	AC3	SOFTWARE	LYS A:111 , THR A:125 , PRO A:126 , ASP A:127 , LYS A:164 , HOH A:727 , HOH A:1058	BINDING SITE FOR RESIDUE NO3 A 371
4	AC4	SOFTWARE	PRO A:5 , PHE A:7 , ASP A:8 , LYS A:11 , TYR A:29 , ARG A:33 , GLU A:93 , ASP A:305 , HOH A:702 , HOH A:827	BINDING SITE FOR RESIDUE NO3 A 2
5	AC5	SOFTWARE	PRO A:116 , TRP A:117 , HIS A:157 , HOH A:397 , HOH A:485 , HOH A:613 , HOH A:795 , HOH A:797	BINDING SITE FOR RESIDUE GOL A 372

(no "SS Bond" information available for 3IAR)

Asymmetric/Biological Unit

No.	Residues
1	Glu A:113	-	Pro A:114

Asymmetric/Biological Unit (34, 34)

								dbSNP	PDB
No.	Source	Variant ID	Variant			UniProt ID	Status	ID	Chain	Variant
01	UniProt	VAR_002209	D	8	N	ADA_HUMAN	Polymorphism	73598374	A	D	8	N
02	UniProt	VAR_002210	H	15	D	ADA_HUMAN	Disease (ADASCID)	121908725	A	H	15	D
03	UniProt	VAR_002211	G	20	R	ADA_HUMAN	Disease (ADASCID)	121908724	A	G	20	R
04	UniProt	VAR_002212	G	74	C	ADA_HUMAN	Disease (ADASCID)	121908730	A	G	74	C
05	UniProt	VAR_002213	R	76	W	ADA_HUMAN	Disease (ADASCID)	121908736	A	R	76	W
06	UniProt	VAR_002214	K	80	R	ADA_HUMAN	Polymorphism	11555566	A	K	80	R
07	UniProt	VAR_002215	A	83	D	ADA_HUMAN	Disease (ADASCID)	121908726	A	A	83	D
08	UniProt	VAR_076954	Y	97	C	ADA_HUMAN	Unclassified (ADASCID)	267606634	A	Y	97	C
09	UniProt	VAR_002216	R	101	L	ADA_HUMAN	Disease (ADASCID)	121908720	A	R	101	L
10	UniProt	VAR_002218	R	101	Q	ADA_HUMAN	Disease (ADASCID)	28930970	A	R	101	Q
11	UniProt	VAR_002217	R	101	W	ADA_HUMAN	Disease (ADASCID)	28930969	A	R	101	W
12	UniProt	VAR_076955	L	106	V	ADA_HUMAN	Unclassified (ADASCID)	267606635	A	L	106	V
13	UniProt	VAR_002219	L	107	P	ADA_HUMAN	Disease (ADASCID)	121908739	A	L	107	P
14	UniProt	VAR_002220	V	129	M	ADA_HUMAN	Disease (ADASCID)	121908731	A	V	129	M
15	UniProt	VAR_002221	G	140	E	ADA_HUMAN	Disease (ADASCID)	121908732	A	G	140	E
16	UniProt	VAR_002222	R	142	Q	ADA_HUMAN	Unclassified	61732239	A	R	142	Q
17	UniProt	VAR_002223	R	149	Q	ADA_HUMAN	Disease (ADASCID)	121908737	A	R	149	Q
18	UniProt	VAR_002224	R	149	W	ADA_HUMAN	Disease (ADASCID)	121908733	A	R	149	W
19	UniProt	VAR_002225	L	152	M	ADA_HUMAN	Polymorphism	121908728	A	L	152	M
20	UniProt	VAR_002226	R	156	C	ADA_HUMAN	Disease (ADASCID)	121908735	A	R	156	C
21	UniProt	VAR_002227	R	156	H	ADA_HUMAN	Disease (ADASCID)	121908722	A	R	156	H
22	UniProt	VAR_002228	V	177	M	ADA_HUMAN	Disease (ADASCID)	121908719	A	V	177	M
23	UniProt	VAR_002229	A	179	D	ADA_HUMAN	Disease (ADASCID)	121908727	A	A	179	D
24	UniProt	VAR_002230	Q	199	P	ADA_HUMAN	Disease (ADASCID)	121908734	A	Q	199	P
25	UniProt	VAR_002231	R	211	C	ADA_HUMAN	Disease (ADASCID)	121908740	A	R	211	C
26	UniProt	VAR_002232	R	211	H	ADA_HUMAN	Disease (ADASCID)	121908716	A	R	211	H
27	UniProt	VAR_002233	A	215	T	ADA_HUMAN	Disease (ADASCID)	114025668	A	A	215	T
28	UniProt	VAR_002234	G	216	R	ADA_HUMAN	Disease (ADASCID)	121908723	A	G	216	R
29	UniProt	VAR_002235	T	233	I	ADA_HUMAN	Polymorphism	121908729	A	T	233	I
30	UniProt	VAR_002236	P	274	L	ADA_HUMAN	Disease (ADASCID)	121908738	A	P	274	L
31	UniProt	VAR_002237	S	291	L	ADA_HUMAN	Disease (ADASCID)	121908721	A	S	291	L
32	UniProt	VAR_002238	P	297	Q	ADA_HUMAN	Disease (ADASCID)	121908718	A	P	297	Q
33	UniProt	VAR_002239	L	304	R	ADA_HUMAN	Disease (ADASCID)	199422327	A	L	304	R
34	UniProt	VAR_002240	A	329	V	ADA_HUMAN	Disease (ADASCID)	121908715	A	A	329	V

SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

Asymmetric/Biological Unit (1, 1)

	PROSITE			UniProtKB		PDB
No.	ID	AC	Description	ID	Location	Count	Location
1	A_DEAMINASE	PS00485	Adenosine and AMP deaminase signature.	ADA_HUMAN	291-297	1	A:291-297

Asymmetric/Biological Unit (12, 12)

	ENSEMBL					UniProtKB			PDB
No.	Transcript ID	Exon	Exon ID	Genome Location	Length	ID	Location	Length	Count	Location	Length
1.1a	ENST00000372874	1a	ENSE00001458877	chr20:43280383-43280216	168	ADA_HUMAN	1-11	11	1	A:5-11	7
1.2	ENST00000372874	2	ENSE00001377681	chr20:43264929-43264868	62	ADA_HUMAN	12-32	21	1	A:12-32	21
1.3	ENST00000372874	3	ENSE00000662275	chr20:43257810-43257688	123	ADA_HUMAN	32-73	42	1	A:32-73	42
1.4a	ENST00000372874	4a	ENSE00000662274	chr20:43255240-43255097	144	ADA_HUMAN	73-121	49	1	A:73-121	49
1.5	ENST00000372874	5	ENSE00000662273	chr20:43254325-43254210	116	ADA_HUMAN	121-160	40	1	A:121-160	40
1.6	ENST00000372874	6	ENSE00000662272	chr20:43252970-43252843	128	ADA_HUMAN	160-202	43	1	A:160-202	43
1.7a	ENST00000372874	7a	ENSE00000662271	chr20:43251719-43251648	72	ADA_HUMAN	203-226	24	1	A:203-226	24
1.7c	ENST00000372874	7c	ENSE00001273220	chr20:43251571-43251470	102	ADA_HUMAN	227-260	34	1	A:227-260	34
1.8	ENST00000372874	8	ENSE00001273210	chr20:43251293-43251229	65	ADA_HUMAN	261-282	22	1	A:261-282	22
1.9a	ENST00000372874	9a	ENSE00001273283	chr20:43249788-43249659	130	ADA_HUMAN	282-325	44	1	A:282-325	44
1.9c	ENST00000372874	9c	ENSE00000844877	chr20:43249042-43248940	103	ADA_HUMAN	326-360	35	1	A:326-360	35
1.10b	ENST00000372874	10b	ENSE00001954810	chr20:43248488-43248163	326	ADA_HUMAN	360-363	4	1	A:360-363	4

Asymmetric/Biological Unit

Reformat:	Number of residues per line = ('0' or empty: single-line sequence representation)
	Number of residues per labelling interval =
	UniProt sequence: complete aligned part

Show mapping:	SCOP domains	CATH domains	Pfam domains	Secondary structure (by author)
	SAPs(SNPs)	PROSITE motifs	Exons
	(details for a mapped element are shown in a popup box when the mouse pointer rests over it)

Chain A from PDB  Type:PROTEIN  Length:360
 aligned with ADA_HUMAN | P00813 from UniProtKB/Swiss-Prot  Length:363

    Alignment length:360
                                                                                                                                                                                                                                                                                                                                                                                                363 
                                    14        24        34        44        54        64        74        84        94       104       114       124       134       144       154       164       174       184       194       204       214       224       234       244       254       264       274       284       294       304       314       324       334       344       354        |-
            ADA_HUMAN     5 PAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNL-   -
               SCOP domains d3iara_ A: Adenosine deaminase (ADA)                                                                                                                                                                                                                                                                                                                                     SCOP domains
               CATH domains 3iarA00 A:5-364 Metal-dependent hydrolases                                                                                                                                                                                                                                                                                                                               CATH domains
               Pfam domains ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Pfam domains
         Sec.struct. author ......eee...hhhhh.hhhhhhhhhhhhh......hhhhhhhhhh.....hhhhhhhhhhhhhhhhh.hhhhhhhhhhhhhhhhhh..eeeeeeeehhhhhh......hhhhh.....hhhhhhhhhhhhhhhhhhhhh.eeeeeeeee..hhhhhhhhhhhhhhh....eeeeeee......hhhhhhhhhhhhhhhhhhh.eeeeee....hhhhhhhhhhh....eeee.hhhhhhhhhhhhhhhh..eeeehhhhhhhh........hhhhhhhhh...eee...hhhhhh.hhhhhhhhhhhhhh.hhhhhhhhhhhhhhh...hhhhhhhhhhhhhhhhh.hhhhhhhhhh. Sec.struct. author
             SAPs(SNPs) (1) ---N------D----R-----------------------------------------------------C-W---R--D-------------C---L----VP---------------------M----------E-Q------Q--M---C--------------------M-D-------------------P-----------C---TR----------------I----------------------------------------L----------------L-----Q------R------------------------V----------------------------------- SAPs(SNPs) (1)
             SAPs(SNPs) (2) ------------------------------------------------------------------------------------------------Q-----------------------------------------------W------H------------------------------------------------------H--------------------------------------------------------------------------------------------------------------------------------------------------------- SAPs(SNPs) (2)
             SAPs(SNPs) (3) ------------------------------------------------------------------------------------------------W----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- SAPs(SNPs) (3)
                    PROSITE ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------A_DEAMI------------------------------------------------------------------- PROSITE
           Transcript 1 (1) 1.1a   Exon 1.2  PDB: A:12-3----------------------------------------Exon 1.4a  PDB: A:73-121 UniProt: 73-121         --------------------------------------Exon 1.6  PDB: A:160-202 UniProt: 160-202  Exon 1.7a  PDB: A:203-22Exon 1.7c  PDB: A:227-260         Exon 1.8              -----------------------------------------------------------------------------1.10- Transcript 1 (1)
           Transcript 1 (2) ---------------------------Exon 1.3  PDB: A:32-73 UniProt: 32-73     -----------------------------------------------Exon 1.5  PDB: A:121-160                -------------------------------------------------------------------------------------------------------------------------Exon 1.9a  PDB: A:282-325 UniProt: 282-325  Exon 1.9c  PDB: A:326-360          ---- Transcript 1 (2)
                 3iar A   5 PAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPDFLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAIDLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGYHTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIFKSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAGQNLA 364
                                    14        24        34        44        54        64        74        84        94       104       114       124       134       144       154       164       174       184       194       204       214       224       234       244       254       264       274       284       294       304       314       324       334       344       354       364

Legend:		→ Mismatch	(orange background)
	-	→ Gap	(green background, '-', border residues have a numbering label)
		→ Modified Residue	(blue background, lower-case, 'x' indicates undefined single-letter code, labelled with number + name)
	x	→ Chemical Group	(purple background, 'x', labelled with number + name, e.g. ACE or NH2)
	extra numbering lines below/above indicate numbering irregularities and modified residue names etc., number ends below/above '\|'

Asymmetric/Biological Unit

Classes(

)

Folds(

)

Superfamilies( (-)

)

Families(

)

Protein Domains( (-)

)

Organisms( (-)

)

Class: Alpha and beta proteins (a/b) (23833)

Fold: TIM beta/alpha-barrel (3956)

Superfamily: Metallo-dependent hydrolases (273)

Family: Adenosine/AMP deaminase (36)

Protein domain: Adenosine deaminase (ADA) (24)

Human (Homo sapiens) [TaxId: 9606] (1)

d3iara_

Asymmetric/Biological Unit

Classes(

)

Architectures( (-)

)

Topologies( (-)

)

Homologous Superfamilies( (-)

)

Organisms( (-)

)

Class: Alpha Beta (26913)

Architecture: Alpha-Beta Barrel (2994)

Topology: TIM Barrel (2806)

Homologous Superfamily: Metal-dependent hydrolases (190)

Human (Homo sapiens) (5)

3iarA00

A:5-364

(no "Pfam Domain" information available for 3IAR)

Asymmetric/Biological Unit(hide GO term definitions)

Chain A (ADA_HUMAN | P00813)

molecular function
	GO:0004000	adenosine deaminase activity	Catalysis of the reaction: adenosine + H2O = inosine + NH3.
	GO:0019239	deaminase activity	Catalysis of the removal of an amino group from a substrate, producing ammonia (NH3).
	GO:0016787	hydrolase activity	Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.
	GO:0046872	metal ion binding	Interacting selectively and non-covalently with any metal ion.
	GO:0005515	protein binding	Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).
	GO:0001883	purine nucleoside binding	Interacting selectively and non-covalently with a purine nucleoside, a compound consisting of a purine base linked either to ribose or deoxyribose.
	GO:0008270	zinc ion binding	Interacting selectively and non-covalently with zinc (Zn) ions.
biological process
	GO:0048541	Peyer's patch development	The process whose specific outcome is the progression of Peyer's patches over time, from their formation to the mature structure. Peyer's patches are typically found as nodules associated with gut epithelium with distinct internal structures including B- and T-zones for the activation of lymphocytes.
	GO:0042110	T cell activation	The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.
	GO:0006154	adenosine catabolic process	The chemical reactions and pathways resulting in the breakdown of adenosine, adenine riboside, a ribonucleoside found widely distributed in cells of every type as the free nucleoside and in combination in nucleic acids and various nucleoside coenzymes.
	GO:0046085	adenosine metabolic process	The chemical reactions and pathways involving adenosine, adenine riboside, a ribonucleoside found widely distributed in cells of every type as the free nucleoside and in combination in nucleic acids and various nucleoside coenzymes.
	GO:0007568	aging	A developmental process that is a deterioration and loss of function over time. Aging includes loss of functions such as resistance to disease, homeostasis, and fertility, as well as wear and tear. Aging includes cellular senescence, but is more inclusive. May precede death and may succeed developmental maturation (GO:0021700).
	GO:0007155	cell adhesion	The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.
	GO:0046061	dATP catabolic process	The chemical reactions and pathways resulting in the breakdown of dATP, deoxyadenosine triphosphate (2'-deoxyadenosine 5'-triphosphate).
	GO:0006157	deoxyadenosine catabolic process	The chemical reactions and pathways resulting in the breakdown of deoxyadenosine, 2-deoxyribosyladenine, one of the four major nucleosides of DNA.
	GO:0048566	embryonic digestive tract development	The process whose specific outcome is the progression of the gut over time, from its formation to the mature structure during embryonic development. The gut is the region of the digestive tract extending from the beginning of the intestines to the anus.
	GO:0002314	germinal center B cell differentiation	The process in which a B cell in the spleen acquires the specialized features of a germinal center B cell. Germinal center B cells are rapidly cycling B cells which have downregulated IgD expression and exhibit high levels of binding by peanut agglutinin (PNA).
	GO:0001821	histamine secretion	The regulated release of histamine by a cell or tissue. It is formed by decarboxylation of histidine and it acts through receptors in smooth muscle and in secretory systems.
	GO:0046101	hypoxanthine biosynthetic process	The chemical reactions and pathways resulting in the formation of hypoxanthine, 6-hydroxy purine, an intermediate in the degradation of adenylate. Its ribonucleoside is known as inosine and its ribonucleotide as inosinate.
	GO:0043103	hypoxanthine salvage	Any process that generates hypoxanthine, 6-hydroxy purine, from derivatives of it without de novo synthesis.
	GO:0001701	in utero embryonic development	The process whose specific outcome is the progression of the embryo in the uterus over time, from formation of the zygote in the oviduct, to birth. An example of this process is found in Mus musculus.
	GO:0046103	inosine biosynthetic process	The chemical reactions and pathways resulting in the formation of inosine, hypoxanthine riboside, a nucleoside found free but not in combination in nucleic acids except in the anticodons of some tRNAs.
	GO:0001889	liver development	The process whose specific outcome is the progression of the liver over time, from its formation to the mature structure. The liver is an exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes.
	GO:0048286	lung alveolus development	The process whose specific outcome is the progression of the alveolus over time, from its formation to the mature structure. The alveolus is a sac for holding air in the lungs; formed by the terminal dilation of air passageways.
	GO:0030324	lung development	The process whose specific outcome is the progression of the lung over time, from its formation to the mature structure. In all air-breathing vertebrates the lungs are developed from the ventral wall of the oesophagus as a pouch which divides into two sacs. In amphibians and many reptiles the lungs retain very nearly this primitive sac-like character, but in the higher forms the connection with the esophagus becomes elongated into the windpipe and the inner walls of the sacs become more and more divided, until, in the mammals, the air spaces become minutely divided into tubes ending in small air cells, in the walls of which the blood circulates in a fine network of capillaries. In mammals the lungs are more or less divided into lobes, and each lung occupies a separate cavity in the thorax.
	GO:0060169	negative regulation of adenosine receptor signaling pathway	Any process that stops, prevents, or reduces the frequency, rate or extent of the adenosine receptor signaling pathway. The adenosine receptor pathway is the series of molecular signals generated as a consequence of an adenosine receptor binding to one of its physiological ligands.
	GO:0043066	negative regulation of apoptotic process	Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
	GO:0042323	negative regulation of circadian sleep/wake cycle, non-REM sleep	Any process that stops, prevents or reduces the duration or quality of non-rapid eye movement (NREM) sleep.
	GO:0050728	negative regulation of inflammatory response	Any process that stops, prevents, or reduces the frequency, rate or extent of the inflammatory response.
	GO:0002686	negative regulation of leukocyte migration	Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte migration.
	GO:0002906	negative regulation of mature B cell apoptotic process	Any process that stops, prevents, or reduces the frequency, rate, or extent of mature B cell apoptotic process.
	GO:0070256	negative regulation of mucus secretion	Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of mucus from a cell or a tissue.
	GO:0060407	negative regulation of penile erection	Any process that stops, prevents, or reduces the rate, frequency or extent of penile erection. Penile erection is the hardening, enlarging and rising of the penis which often occurs in the sexually aroused male and enables sexual intercourse. Achieved by increased inflow of blood into the vessels of erectile tissue, and decreased outflow.
	GO:0070244	negative regulation of thymocyte apoptotic process	Any process that stops, prevents, or reduces the frequency, rate or extent of thymocyte death by apoptotic process.
	GO:0009117	nucleotide metabolic process	The chemical reactions and pathways involving a nucleotide, a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the glycose moiety; may be mono-, di- or triphosphate; this definition includes cyclic nucleotides (nucleoside cyclic phosphates).
	GO:0001890	placenta development	The process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin.
	GO:0030890	positive regulation of B cell proliferation	Any process that activates or increases the rate or extent of B cell proliferation.
	GO:0050870	positive regulation of T cell activation	Any process that activates or increases the frequency, rate or extent of T cell activation.
	GO:0045582	positive regulation of T cell differentiation	Any process that activates or increases the frequency, rate or extent of T cell differentiation.
	GO:0033089	positive regulation of T cell differentiation in thymus	Any process that activates or increases the frequency, rate or extent of T cell differentiation in the thymus.
	GO:0050862	positive regulation of T cell receptor signaling pathway	Any process that activates or increases the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell.
	GO:0046638	positive regulation of alpha-beta T cell differentiation	Any process that activates or increases the frequency, rate or extent of alpha-beta T cell differentiation.
	GO:0050850	positive regulation of calcium-mediated signaling	Any process that activates or increases the frequency, rate or extent of calcium-mediated signaling.
	GO:0002636	positive regulation of germinal center formation	Any process that activates or increases the frequency, rate, or extent of germinal center formation.
	GO:0010460	positive regulation of heart rate	Any process that activates or increases the frequency or rate of heart contraction.
	GO:0045987	positive regulation of smooth muscle contraction	Any process that activates or increases the frequency, rate or extent of smooth muscle contraction.
	GO:0032261	purine nucleotide salvage	Any process which produces a purine nucleotide from derivatives of it, without de novo synthesis.
	GO:0009168	purine ribonucleoside monophosphate biosynthetic process	The chemical reactions and pathways resulting in the formation of purine ribonucleoside monophosphate, a compound consisting of a purine base linked to a ribose sugar esterified with phosphate on the sugar.
	GO:0043101	purine-containing compound salvage	Any process that generates a purine-containing compound, any nucleobase, nucleoside, nucleotide or nucleic acid that contains a purine base, from derivatives of them without de novo synthesis.
	GO:0045580	regulation of T cell differentiation	Any process that modulates the frequency, rate or extent of T cell differentiation.
	GO:0033632	regulation of cell-cell adhesion mediated by integrin	Any process that modulates the frequency, rate, or extent of cell-cell adhesion mediated by integrin.
	GO:0045187	regulation of circadian sleep/wake cycle, sleep	Any process that modulates the frequency, rate or extent of sleep; a readily reversible state of reduced awareness and metabolic activity that occurs periodically in many animals.
	GO:0042493	response to drug	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a drug stimulus. A drug is a substance used in the diagnosis, treatment or prevention of a disease.
	GO:0042542	response to hydrogen peroxide	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus.
	GO:0001666	response to hypoxia	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.
	GO:0043278	response to morphine	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a morphine stimulus. Morphine is an opioid alkaloid, isolated from opium, with a complex ring structure.
	GO:0033197	response to vitamin E	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a vitamin E stimulus.
	GO:0001829	trophectodermal cell differentiation	The process in which a relatively unspecialized cell acquires the specialized features of a trophectoderm cell.
	GO:0046111	xanthine biosynthetic process	The chemical reactions and pathways resulting in the formation of xanthine, 2,6-dihydroxypurine, a purine formed in the metabolic breakdown of guanine but not present in nucleic acids.
cellular component
	GO:0030054	cell junction	A cellular component that forms a specialized region of connection between two or more cells or between a cell and the extracellular matrix. At a cell junction, anchoring proteins extend through the plasma membrane to link cytoskeletal proteins in one cell to cytoskeletal proteins in neighboring cells or to proteins in the extracellular matrix.
	GO:0009986	cell surface	The external part of the cell wall and/or plasma membrane.
	GO:0005737	cytoplasm	All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
	GO:0031410	cytoplasmic vesicle	A vesicle found in the cytoplasm of a cell.
	GO:0060205	cytoplasmic vesicle lumen	The volume enclosed by a cytoplasmic vesicle.
	GO:0005829	cytosol	The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
	GO:0032839	dendrite cytoplasm	All of the contents of a dendrite, excluding the surrounding plasma membrane.
	GO:0009897	external side of plasma membrane	The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface.
	GO:0005615	extracellular space	That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.
	GO:0005764	lysosome	A small lytic vacuole that has cell cycle-independent morphology and is found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions.
	GO:0016020	membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
	GO:0043025	neuronal cell body	The portion of a neuron that includes the nucleus, but excludes cell projections such as axons and dendrites.
	GO:0005886	plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

Asymmetric/Biological Unit
	Complete Structure
		Jena3D(integrated viewing of ligand, site, SAP, PROSITE, SCOP information)
		WebMol \| AstexViewer[tm]@PDBe (Java Applets, require no local installation except for Java; loading may be slow)
		STRAP (Java WebStart application, automatic local installation, requires Java; full application with system access!)
		RasMol (require local installation)
		Molscript (VRML) (requires installation of a VRML viewer; select preferred view via VRML and generate a mono or stereo PDF format file)

	Ligands, Modified Residues, Ions
		3D1	[ RasMol \| Jena3D ]	+environment [ RasMol \| Jena3D ]
		GOL	[ RasMol \| Jena3D ]	+environment [ RasMol \| Jena3D ]
		NI	[ RasMol \| Jena3D ]	+environment [ RasMol \| Jena3D ]
		NO3	[ RasMol \| Jena3D ]	+environment [ RasMol \| Jena3D ]

	Sites
		AC1	[ RasMol ]	+environment [ RasMol ]
		AC2	[ RasMol ]	+environment [ RasMol ]
		AC3	[ RasMol ]	+environment [ RasMol ]
		AC4	[ RasMol ]	+environment [ RasMol ]
		AC5	[ RasMol ]	+environment [ RasMol ]

	Cis Peptide Bonds
		Glu A:113 - Pro A:114	[ RasMol ]

Jmol
	protein: cartoon or spacefill or dots and stick; nucleic acid: cartoon and stick; ligands: spacefill; active site: stick [ Asym./Biol. Unit PNG format \| Asym./Biol. Unit - sites PNG format ](automatic orientation, automatically generated)
Molscript
	protein, nucleic acid: cartoon; ligands: spacefill; active site: ball and stick [ mono PDF format \| stereo PDF format ](default orientation, automatically generated)

Access by PDB/NDB ID
	3iar
		Family and Domain Information	:	ProDom \| SYSTERS
		General Structural Information	:	GlycoscienceDB \| MMDB \| NDB \| OCA \| PDB \| PDBe \| PDBj \| PDBsum \| PDBWiki \| PQS \| PROTEOPEDIA
		Orientation in Membranes	:	OPM
		Protein Surface	:	SURFACE
		Secondary Structure	:	DSSP (structure derived) \| HSSP (homology derived)
		Structural Genomics	:	GeneCensus
		Structural Neighbours	:	CE \| VAST
		Structure Classification	:	CATH \| Dali \| SCOP
		Validation and Original Data	:	BMRB Data View \| BMRB Restraints Grid \| EDS \| PROCHECK \| RECOORD \| WHAT_CHECK

Access by UniProt ID/Accession number
	ADA_HUMAN \| P00813
		Comparative Protein Structure Models	:	ModBase
		Genomic Information	:	Ensembl
		Protein-protein Interaction	:	DIP
		Sequence, Family and Domain Information	:	InterPro \| Pfam \| SMART \| UniProtKB/SwissProt

Access by Enzyme Classificator (EC Number)
	3.5.4.4
		General Enzyme Information	:	BRENDA \| EC-PDB \| Enzyme \| IntEnz
		Pathway	:	KEGG \| MetaCyc

Access by Disease Identifier (MIM ID)
	102700
		Disease Information	:	OMIM

Access by GenAge ID
	(no 'GenAge ID' available)
		Age Related Information	:	GenAge

Access by PDB/NDB ID
		Domain Information	:	XDom
		Interatomic Contacts of Structural Units	:	CSU
		Ligand-protein Contacts	:	LPC
		Protein Cavities	:	castP
		Sequence and Secondary Structure	:	PDBCartoon
		Structure Alignment	:	STRAP(Java WebStart application, automatic local installation, requires Java; full application with system access!)
		Structure and Sequence Browser	:	STING

Access by UniProt ID/Accession number
	ADA_HUMAN \| P00813
		Protein Disorder Prediction	:	DisEMBL \| FoldIndex \| GLOBPLOT (for more information see DisProt)

UniProtKB/Swiss-Prot
	ADA_HUMAN \| P00813	:	1m7m

1krm	CRYSTAL STRUCTURE OF BOVINE ADENOSINE DEAMINASE COMPLEXED WITH 6-HYDROXYL-1,6-DIHYDROPURINE RIBOSIDE

Description

Compounds

Structural Features

Chains, Units

Ligands, Modified Residues, Ions (4, 5)

Sites (5, 5)

SS Bonds (0, 0)

Cis Peptide Bonds (1, 1)

Sequence-Structure Mapping

SAPs(SNPs)/Variants (34, 34)

PROSITE Motifs (1, 1)

Exons (12, 12)

Sequences/Alignments

Classification and Annotation

SCOP Domains (1, 1)

CATH Domains (1, 1)

Pfam Domains (0, 0)

Gene Ontology (72, 72)

Visualization

Interactive Views

Still Images

Databases and Analysis Tools

Databases

Analysis Tools

Related Entries

Entries Sharing at Least One Protein Chain (UniProt ID)

Related Entries Specified in the PDB File